Seventeen elderly patients with advanced progressive non small cell lung cancer (NSCLC) were treated with oral etoposide at the daily dose of 100 mg for 14 days every 3-4 weeks with pharmacokinetic monitoring. One partial response and 6 stabilizations were documented with a median overall duration of 13 weeks (range 8-32). The median survival was 24 weeks with an apparent advantage for non-progressive patients (40 weeks vs. 18 weeks). The treatment was well tolerated especially by those patients without concomitant illness, suggesting the crucial role of a careful selection of the geriatric population. Toxicity was not related to the etoposide plasma level, but was clearly dependent on comorbidity. A geriatric assessment rather than chronological age therefore appears to be more reliable in the selection of elderly patients for clinical trials. The easy self-management, favorable toxicity profile and synergy with other compounds makes oral etoposide suitable for further clinical- pharmacological studies in elderly patients. © E.S.I.F.T. srl - Firenze.
|Titolo:||Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study|
|Data di pubblicazione:||2006|
|Citazione:||Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study / SORIO R; TOFFOLI G; CRIVELLARI D; BEARZ A; CORONA G; COLUSSI AM; LIBRA M; TALAMINI R; VERONESI A. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 18:2(2006), pp. 91-188.|
|Appare nelle tipologie:||1.1 Articolo in rivista|